Brand Intelligence Graph
Company Overview
About ForSight Robotics
ForSight Robotics is developing the Oryom — a surgical robot designed to reach any anatomical point within the human eye, enabling robotic cataract surgery, retinal procedures, and glaucoma interventions with precision exceeding human capability. The company raised $125 million in Series B financing in June 2025 and is launching its first human cataract trials in 2026, making it one of the most clinically advanced ophthalmic robotics companies globally. If the 2026 trial results are positive, an FDA submission pathway follows for the world's first robotic eye surgery system at clinical scale.
Business Model & Competitive Advantage
Cataract surgery is the highest-volume surgical procedure globally — approximately 28 million procedures annually — and the tremor problem in manual surgery (even experienced surgeons have physiological hand tremor of 50-100 microns) is the primary source of intraoperative complications. Oryom's robotic guidance eliminates this constraint, with sub-micron positioning accuracy enabling surgical maneuvers in the vitreous cavity that human hands cannot reliably execute.
Competitive Landscape 2025–2026
The ophthalmic surgical robotics market is effectively untapped: Intuitive Surgical dominates general laparoscopy but has no ophthalmic product; CMR Surgical and Stryker operate in orthopedic and abdominal surgery. ForSight faces minimal competition from established robotics companies while targeting a surgical volume that dwarfs most other specialties.
Key Differentiators
Emerging Innovator
ForSight Robotics is an emerging player bringing innovative solutions to the MedTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare ForSight Robotics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ForSight Robotics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ForSight Robotics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ForSight Robotics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →